4-Methyl Erlotinib Hydrochloride

4-Methyl Erlotinib Hydrochloride Basic information
Product Name:4-Methyl Erlotinib Hydrochloride
Synonyms:N-[(3-Ethynyl-4-Methyl)phenyl]-6,7-bis(2-Methoxyethoxy)-4-quinazolinaMine Hydrochloride;OSI-597;Erlotinib iMpurity G;N-(3-ethynyl-4-methylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride;4-Methyl Erlotinib Hydrochloride;N-(3-ETHYNYL-4-METHYLPHENYL)-6,7-BIS(2-METHOXYETHOXY)QUINAZOLIN-4-AMINE HCL;4-methyl Erlotinib;Erlotinib 4-Methyl Analog
CAS:1346601-52-2
MF:C23H25N3O4
MW:407.46
EINECS:
Product Categories:Amines;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:1346601-52-2.mol
4-Methyl Erlotinib Hydrochloride Structure
4-Methyl Erlotinib Hydrochloride Chemical Properties
Melting point 224-228°C (dec.)
Boiling point 567.5±50.0 °C(Predicted)
density 1.23±0.1 g/cm3(Predicted)
storage temp. -20°C Freezer
solubility Chloroform (Slightly), DMSO, Methanol (Slightly)
pka5.33±0.30(Predicted)
form Solid
color Pale Pink to Pale Brown
Safety Information
MSDS Information
4-Methyl Erlotinib Hydrochloride Usage And Synthesis
UsesErlotinib (E625000) derivative as internal standard for HPLC.
Biological Activity4-methyl erlotinib is an analog of erlotinib by the addition of a methyl group at the four position of the phenyl group. erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (egfr) [1].the epidermal growth factor receptor (egfr) autocrine pathway has been important for cancer development and progression, including cell proliferation, apoptosis, angiogenesis, and metastatic spread [2].erlotinib inhibits egfr-associated kinase activity by binding to the egf-activated receptor, with the phenyl group at one end sequestered in a hydrophobic pocket of the kinase domain and the ether linkages at the opposite end projecting into solvent [1].erlotinib can prolong survival in patients with non–small-cell lung cancer after first-line or second-line chemotherapy [3].
references[1] stamos, j. ,sliwkowski, m.x. and eigenbrot, c. structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. the journal of biological chemisty 277(48), 46265-46272 (2002).
[2] ciardiello f, tortora g. a novel approach in the treatment of cancer: targeting the epidermal growth factor receptor[j]. clinical cancer research, 2001, 7(10): 2958-2970.
[3] shepherd f a, rodrigues pereira j, ciuleanu t, et al. erlotinib in previously treated non–small-cell lung cancer[j]. new england journal of medicine, 2005, 353(2): 123-132.
4-Methyl Erlotinib Hydrochloride Preparation Products And Raw materials
Didesmethyl Erlotinib Hydrochloride Salt Erlotinib iMpurity 2 4-Quinazolinamine,N-(3-ethenylphenyl)-6,7-bis(2-methoxyethoxy)-,hydrochloride(1:1) Erlotinib D6 HCl Erlotinib Impurity 20 6,7-bis(2-methoxyethoxy)-N-phenylquinazolin-4-amine OSI-420 Erlotinib iMpurity B Erlotinib hydrochloride Erlotinib 2,3,5-Trimethylpyridine-1-Oxide Erlotinib iMpurity 3 3-Aminophenylacetylene 4-Chloro-6,7-bis-(2-chloroethoxy)quinazoline 6,7-Bis-(2-methoxyethoxy)-4(3H)-quinazolinone Desmethyl Erlotinib Acetate Erlotinib iMpurity Erlotinib

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.